Showing 8221-8230 of 10543 results for "".
- Analysis: Nicotinamide Not Linked to Elevated MACE Riskhttps://practicaldermatology.com/news/study-nicotinamide-not-linked-to-mace-risk/2471380/Results from a new retrospective cohort study suggest nicotinamide exposure was not associated with an increased risk of major adverse cardiovascular events (MACE). The analysis included data from 13,108 patients in the Vanderb
- Cardio-Dermatology: Multidisciplinary Care Essential for Reducing Multifaceted Riskhttps://practicaldermatology.com/news/cardio-dermatology-multidisciplinary-care-essential-for-reducing-multifaceted-risk/2471287/Chronic skin conditions like psoriasis and atopic dermatitis (AD) are more than skin-deep—they carry significant risks for heart disease and require special attention, according to a compelling presentation given at Masterclasses in Dermatology 2025 in Sarasota. In her talk, Brittany Weber
- Patient-Centric Guidelines for Generalized Pustular Psoriasis Management Unveiledhttps://practicaldermatology.com/news/patient-centric-guidelines-for-generalized-pustular-psoriasis-management-unveiled/2471251/A global Delphi study has established holistic treatment goals for generalized pustular psoriasis (GPP), integrating both physician and patient perspectives. The consensus study included participants from 24 countries, and acc
- Dr. Armstrong Discusses Combination Therapies for Psoriasishttps://practicaldermatology.com/news/Dr-Armstrong-Discusses-Combination-Therapies-Psoriasis/2471212/The quality and variety of biologic therapeutic options available today should give dermatologists more confidence than ever in treating psoriasis, according to April Armstrong, MPH, MPH. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Armstrong discuss
- Dupixent Moves Closer to FDA Approval for Bullous Pemphigoidhttps://practicaldermatology.com/news/dupixent-moves-closer-to-fda-approval-for-bullous-pemphigoid/2471173/Dupixent® (dupilumab) significantly improved sustained disease remission in adults with bullous pemphigoid (BP) compared to placebo, according to an announcement from the manufacturers, Regeneron Pharmaceuticals and Sanofi. Acc
- Rituximab Infusion Reduces Relapse in High-risk Pemphigus Patientshttps://practicaldermatology.com/news/rituximab-infusion-reduces-relapse-in-high-risk-pemphigus-patients/2471143/New research shows rituximab infusion at six months significantly reduced relapse risk in patients with pemphigus who had predictors of relapse. Researchers for the multicenter cohort study conducted in France included 87 pati
- New Dupilumab Data for CSU to Be Presented at AAAAI Meetinghttps://practicaldermatology.com/news/New-Dupilumab-Data-CSU-Be-Presented-AAAAI-Meeting/2471105/New phase 3 data on dupilumab for chronic spontaneous urticaria (CSU) will be among 24 abstracts presented by Sanofi at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California, from February 28 to March 3. The dupilumab CSU data from the LIBER
- Pacific Northwest Practice Hiringhttps://practicaldermatology.com/news/Pacific-Northwest-Practice-Hiring/2471098/Clear Choice Dermatology announced it is seeking a board-certified dermatologist to work in its locations in Portland, Oregon, or Salem, Oregon. Clear Choice has 11 locations throughout Oregon and Washington. Owner and Chief Medical Officer Collin Blattner, DO, FAAD, is a member of Pra
- DELTA TEEN: Positive Results for Delgocitinib in Adolescent Chronic Hand Eczemahttps://practicaldermatology.com/news/delta-teen-positive-results-for-delgocitinib-in-adolescent-chronic-hand-eczema/2471096/Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged 12–17, according to a news release from the manufacturer. The DELTA TEEN trial was a 16-w
- Baricitinib Enhances Phototherapy Efficacy in Adults with Active Vitiligohttps://practicaldermatology.com/news/baricitinib-enhances-phototherapy-efficacy-in-severe-atopic-dermatitis/2471046/Baricitinib combined with narrowband UV-B achieved a modest reduction in disease severity in adults with severe, active nonsegmental vitiligo, but did not meet the prespecified threshold for sufficient repigmentation, new research revealed. The trial enrolled 49 adul